Category: Pharmaceutical Industry
-
âThe future of medicine and diagnosticsâ: behind the patent enforcement strategy of biotech tools company SeerÂ
Seerâs VP of Legal, George Fox, discusses the challenges that its patent portfolio has recently overcome, and the enforcement campaign it has launched in the U.S.Â
-
Canada’s Supreme Court clarifies (un)patentability of medical treatment methods in landmark decision
Janssen and Pharmascience have been locked in litigation since 2020 over the former’s antipsychotic patent, which includes claims directed towards dosage regimens.
-
Covid-19 vaccine makers Moderna and Pfizer hit with Sanofi suits over mRNA delivery tech
Sanofi and Translate Bio effectively abandoned their own Covid-19 vaccine effort in 2021 after the former acquired the latter.
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyethâs cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
Federal Circuit applies Third Circuit law to vacate District of Delaware’s waiver of preliminary injunction bond
The district court made the rare decision to waive Otsuka Pharmaceutical’s requirement to post a bond after granting it a preliminary injunction against Hetero Labs’ generic competitor.
-
Federal Circuit affirms invalidation of Enantaâs Paxlovid-related patent: finds âtypoâ defense insufficient to fix written description gap in provisional filing
The United States Court of Appeals for the Federal Circuit has affirmed the invalidation of Enantaâs Paxlovid-related patent, rejecting its bid to blame a one-carbon typo in its provisional filing, and leaving Pfizerâs earlier disclosure now free to anticipate the claims.
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgenâs subsidiary Teneobio has infringed one of competitor Harbour Antibodiesâs antibody-related patents and owes over $20 million in damages.
-
Incyte acquires bleeding-disorder biotech Vega Therapeutics as Jakafi patent cliff looms
Incyte will pay $1.25 billion upfront for Vega Therapeutics, with up to $750 million more in sales milestones. The $2.4 billion-a-year drug loses U.S. exclusivity in December 2028 after a pediatric extension.
-
Supreme Court holds generics maker Hikma not liable for induced infringement: inducement must be “clear” and “affirmative”
A unanimous Supreme Court says the Federal Circuit has been on the wrong track lately by loosening the standard for induced infringement.
-
Podcast: marking UPCâs three-year anniversary with UPC litigator Dr. Wim Maas (Winston Taylor)
In our latest podcast episode, ip fray interviewed Wim Maas, partner and trial attorney at Winston Taylor, who is a very frequent user of the Unified Patent Court.